Pfizer will pay $11.6 billion for Biohaven

Pfizer said it will pay $11.6 billion to buy Biohaven Pharmaceutical Holding, betting big on its ability to boost sales of the top-selling pill in a new class of migraine drugs. Shares of Biohaven jumped 70% to $141.31, while shares of Pfizer rose slightly to $48.83.

Share this post:

Related Posts
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore
WordPress Cookie Plugin by Real Cookie Banner